The POM Wonderful Decision and Claim Substantiation Standards

by Richard B. Newman
On January 30, the D.C. Circuit Court of Appeals held in POM Wonderful, LLC, et al. v. Federal Trade Commission that the FTC did not have an adequate basis to require POM Wonderful, LLC to conduct a minimum of two successful “randomized and controlled human clinical trials” before making advertising claims regarding product efficacy and disease prevention.Read the full article